Press Releases
View printer-friendly version << Back
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Jefferies London Healthcare Conference : Fireside chat onTuesday, November 14 at5:00 p.m. GMT /12:00 p.m. ET .- Piper Sandler 35th Annual Healthcare Conference: Fireside chat on
Wednesday, November 29 at11:30 a.m. ET .
A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.
About
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687
Media Contact:
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
Source: Avadel Pharmaceuticals plc